Eli Lilly and Co.

UPDATE: Lilly, others see stock slide after drug rejection

October 20, 2010
Bloomberg News
Stock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
More

Some Lilly-paid docs sport spotty records

October 20, 2010
J.K. Wall
Eli Lilly and Co. paid more than $102 million last year and early this year to physicians for talking up Lilly drugs to other doctors. Yet 88 of the doctors Lilly pays have been sanctioned by state medical boards.
More

FDA demands more tests on new Lilly diabetes drug

October 19, 2010
J.K. Wall
Eli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly version of diabetes drug Byetta, a potential billion-dollar drug.
More

Lilly to close drug discovery center in Singapore

October 18, 2010
Bloomberg News
Indianapolis-based Eli Lilly and Co. will close its drug discovery center in Singapore, three years into a five-year, $150 million plan to expand it.
More

Lilly falls short on 'field goal' attempt

October 13, 2010
J.K. Wall
Eli Lilly and Co.’s “miss” on a new use for its cancer drug Alimta was a rare failure to get an existing drug approved for a new use—even though the company has struggled mightily to get entirely new drugs to market.
More

Lilly's Erbitux shows mixed results in cancer studies

October 11, 2010
Bloomberg News
In combination with chemotherapy, the drug failed to help colon-cancer patients in a European trial but did delay the spread of breast cancer in some patients with a certain type of aggressive tumor.
More

Coordinating Lilly 'Day of Service' a major undertaking

October 7, 2010
Scott Olson
Getting 8,500 volunteers to where they're supposed to be along Interstate 70 relies on a system of color-coded passes. By 6 p.m. Thursday, they'll have planted 1,600 trees and 72,000 shrubs and perennials (with photo gallery).
More

Consultants: Pharma industry facing huge changes

October 6, 2010
J.K. Wall
Heitzman_WatchVideoTo date, most analysts say health reform turned out pretty well for the pharmaceutical industry. But a detailed analysis by Deloitte Consulting says the indirect effects of reform will deliver a gut punch to the industry that will lead to full-scale transformation akin to what the telecommunications world has seen over the past three decades.
More

Drugmakers’ ‘doughnut hole’ deal to shave sales

October 1, 2010
Bloomberg News
Drugmakers including Pfizer Inc., AstraZeneca, Bristol-Myers Squibb Co. and Eli Lilly and Co. may provide more than $2 billion in drug discounts to senior citizens next year under a deal pharmaceutical companies made with the White House.
More

Lilly sues drug distributor over generic Zyprexa sales

September 29, 2010
Bloomberg News
Celesio's Lloyds Pharmacy and Aah Pharmaceuticals businesses sold about 800,000 tablets of generic Zyprexa before agreeing in 2008 to halt sales, Lilly said in a complaint filed in the High Court in London.
More

$150M 'North of South' project moving ahead

September 27, 2010
 IBJ Staff
Officials are announcing details of an ambitious downtown development planned for 10 acres Eli Lilly and Co. owns near its Indianapolis headquarters. The project will include a hotel, apartments, restaurants and retail space and a YMCA.
More

Lilly discovers social media

September 22, 2010
J.K. Wall
Eli Lilly and Co. launched its own blog this month, dubbed LillyPad, to try to start discussions about public policy and corporate social responsibility. The Indianapolis-based drugmaker also launched an accompanying Twitter feed.
More

Lilly wins reversal of class action in Zyprexa suit

September 10, 2010
Bloomberg News
A U.S. appeals court in New York threw out a September 2008 ruling that said plaintiffs could pursue as a group claims that Zyprexa marketing caused them to pay more for the drug than what it was worth. The plaintiffs were seeking $6.8 billion in damages.
More

Lilly investing up to $150M in VC funds

September 8, 2010
Bloomberg News
The three venture funds, which will focus on drug development, may be worth a total of $750 million, up to $250 million each, and Lilly will contribute as much as 20 percent of the money.
More

Lab used by Lilly, peers accused of animal cruelty

September 8, 2010
 IBJ Staff and Associated Press
An investigation found that lab employees kicked, threw, and dragged dogs; lifted rabbits by their ears and puppies by their throats; violently slammed cats into cages; and exposed animals to toxic chemicals.
More

CEO says Lilly still not interested in huge acquisitions

September 7, 2010
 IBJ Staff and Bloomberg News
Lilly remains disinterested in making big acquisitions and aims to rely on the company’s own pipeline, CEO John Lechleiter said Tuesday, re-emphasizing a strategy he has outlined several times in the past year.
More

Appeals court ruling upholds Lilly's Evista patents

September 1, 2010
Bloomberg News
Eli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic version of the Evista osteoporosis treatment before March 2014.
More

After health reform, Lilly looking for more

September 1, 2010
J.K. Wall
The health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives of the bill—and calling for further government efforts to help pharmaceutical research and development.
More

Lilly wins ban of generic Strattera pending appeal

August 31, 2010
Bloomberg News
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly's request to prevent sales until the court rules on a judge's decision invalidating a patent on the medicine.
More

A half-century later, Indiana Landmarks returns to roots

August 28, 2010
Cory Schouten
Old Centrum Watch VideoBankrolled by yet another multimillionaire, the historic preservation group is preparing to move into a new headquarters in Old Centrum, a former church now undergoing a big renovation.
More

Lilly wins further delay in sales of Strattera copies

August 26, 2010
Bloomberg News
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would translate into an average $1.22 million in sales.
More

Diabetes research pioneer Kirtley dies at 96

August 25, 2010
Associated Press
Diabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a groundbreaking Eli Lilly researcher.
More

Lilly woes take notch out of debt rating

August 25, 2010
J.K. Wall
Even with debt levels at Eli Lilly and Co. at paltry lows, a string of bad news finally forced Standard & Poor’s to lower its rating on the company’s senior unsecured debt. But the New York-based agency said it believes the Indianapolis-based drugmaker will eventually break its string of bad luck on developing new products.
More

Lilly gains panel's backing to expand Cymbalta use

August 19, 2010
Bloomberg News
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis of studies in lower back pain and osteoarthritis of the knee.
More

Lilly wins temporary ban on sales of Strattera copies

August 19, 2010
Bloomberg News
The invalidation of Lilly's Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug, which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am not by any means judging whether this is a good or bad project. It's pretty simple, the developers are not showing a hardship or need for this economic incentive. It is a vacant field, the easiest for development, and the developer already has the money to invest $26 million for construction. If they can afford that, they can afford to pay property taxes just like the rest of the residents do. As well, an average of $15/hour is an absolute joke in terms of economic development. Get in high paying jobs and maybe there's a different story. But that's the problem with this ask, it is speculative and users are just not known.

  2. Shouldn't this be a museum

  3. I don't have a problem with higher taxes, since it is obvious that our city is not adequately funded. And Ballard doesn't want to admit it, but he has increased taxes indirectly by 1) selling assets and spending the money, 2) letting now private entities increase user fees which were previously capped, 3) by spending reserves, and 4) by heavy dependence on TIFs. At the end, these are all indirect tax increases since someone will eventually have to pay for them. It's mathematics. You put property tax caps ("tax cut"), but you don't cut expenditures (justifiably so), so you increase taxes indirectly.

  4. Marijuana is the safest natural drug grown. Addiction is never physical. Marijuana health benefits are far more reaching then synthesized drugs. Abbott, Lilly, and the thousands of others create poisons and label them as medication. There is no current manufactured drug on the market that does not pose immediate and long term threat to the human anatomy. Certainly the potency of marijuana has increased by hybrids and growing techniques. However, Alcohol has been proven to destroy more families, relationships, cause more deaths and injuries in addition to the damage done to the body. Many confrontations such as domestic violence and other crimes can be attributed to alcohol. The criminal activities and injustices that surround marijuana exists because it is illegal in much of the world. If legalized throughout the world you would see a dramatic decrease in such activities and a savings to many countries for legal prosecutions, incarceration etc in regards to marijuana. It indeed can create wealth for the government by collecting taxes, creating jobs, etc.... I personally do not partake. I do hope it is legalized throughout the world.

  5. Build the resevoir. If built this will provide jobs and a reason to visit Anderson. The city needs to do something to differentiate itself from other cities in the area. Kudos to people with vision that are backing this project.

ADVERTISEMENT